147 results on '"Campbell, Aimee N.C."'
Search Results
2. Development of a brief stigma and perceptions questionnaire for pharmacists: An exploratory factor analysis approach in New York state counties enrolled in the healing communities study
3. Wiidookaage'win: Beta-test of a Facebook group intervention for Native women to support opioid use recovery
4. Culturally tailored digital therapeutic for substance use disorders with urban Indigenous people in the United States: A randomized controlled study
5. Contributors
6. First wave of scalable digital therapeutics: Internet-based programs for direct-to-consumer standalone care for mental health and addiction
7. Predictors of Urine Toxicology and Other Biologic Specimen Missingness in Randomized Trials of Substance Use Disorders
8. Using digital technologies in clinical trials: Current and future applications
9. A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.
10. Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study
11. Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives
12. Experiences of and recommendations for LGBTQ+-affirming substance use services: A qualitative study with LGBTQ+ people who use opioids and other drugs
13. Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial
14. Decline in Herpes Simplex Virus Type 2 Among Non-Injecting Heroin and Cocaine Users in New York City, 2005 to 2014 : Prospects for Avoiding a Resurgence of Human Immunodeficiency Virus
15. Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder
16. Exploring the performance of during-treatment substance use outcome measures in predicting longer-term psychosocial functioning and post-treatment abstinence
17. Using e-technologies in clinical trials
18. Chapter 3 - First wave of scalable digital therapeutics: Internet-based programs for direct-to-consumer standalone care for mental health and addiction
19. Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States
20. Intimate partner violence outcomes in women with PTSD and substance use: A secondary analysis of NIDA Clinical Trials Network “Women and Trauma” Multi-site Study
21. Addiction Research Training Programs: Four Case Studies and Recommendations for Evaluation
22. Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: An example from the NIDA Clinical Trials Network
23. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone
24. Engagement patterns with a digital therapeutic for substance use disorders: Correlations with abstinence outcomes
25. Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse
26. Comparison of 2 Measures of HIV Sexual Risk Behavior in Women in Outpatient Drug Treatment Programs
27. Technology-Based Behavioral Interventions for Alcohol and Drug Use Problems
28. Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network
29. Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults
30. Methodological innovation to increase the utility and efficiency of psychotherapy research for patients with co-occurring mental health and substance use disorders
31. Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders
32. Corrigendum to “Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse” [Journal of Substance Abuse Treatment 131 (2021) 108447]
33. Corrigendum to “Model and approach for assessing implementation context and fidelity in the HEALing Communities Study” [Drug Alcohol Depend. 217 (2020) 108330]
34. Sublingual Buprenorphine-Naloxone Compared With Injection Naltrexone for Opioid Use Disorder: Potential Utility of Patient Characteristics in Guiding Choice of Treatment
35. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure
36. Using community engagement to implement evidence-based practices for opioid use disorder: A data-driven paradigm & systems science approach
37. Factor structure and psychometric properties of the Connor–Davidson resilience scale (CD-RISC) in individuals with opioid use disorder
38. Associations between Post-Traumatic Stress Symptoms, Stimulant Use, and Treatment Outcomes: A Secondary Analysis of NIDAʼs Women and Trauma Study
39. Characteristics of an Outpatient Treatment Sample by Primary Substance of Abuse
40. The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices
41. Model and approach for assessing implementation context and fidelity in the HEALing Communities Study
42. Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis
43. Substance Use and Mental Health in Emerging Adult Vs Older Adult Men and Women With Opioid Use Disorder
44. Perspectives on trauma and the design of a technology-based trauma-informed intervention for women receiving medications for addiction treatment in community-based settings
45. Do Treatment Improvements in PTSD Severity Affect Substance Use Outcomes? A Secondary Analysis From a Randomized Clinical Trial in NIDAʼs Clinical Trials Network
46. Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone
47. DSM-5 substance use disorder symptom clusters and HIV antiretroviral therapy (ART) adherence
48. Understanding site variability in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders
49. Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis
50. DSM-5 substance use disorder symptom clusters and HIV antiretroviral therapy (ART) adherence.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.